A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

BACKGROUND: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist li...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Michael, Salimi, Hamid, Duncan, Renee, Wilkinson, Brendan L, Chikere, Kelechi, Moore, Miranda S, Webb, Nicholas E, Zappi, Helena, Sterjovski, Jasminka, Flynn, Jacqueline K, Ellett, Anne, Gray, Lachlan R, Lee, Benhur, Jubb, Becky, Westby, Mike, Ramsland, Paul A, Lewin, Sharon R, Payne, Richard J, Churchill, Melissa J, Gorry, Paul R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648390/
https://www.ncbi.nlm.nih.gov/pubmed/23602046
http://dx.doi.org/10.1186/1742-4690-10-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648390/
https://www.ncbi.nlm.nih.gov/pubmed/23602046
http://dx.doi.org/10.1186/1742-4690-10-43

Ejemplares similares